uniQure Q1 net loss $53.5M ($0.85/share); AMT-130 UK MAA on track for Q3

uniQure N.V.

2026-Q1 EPS reported -$0.85 revenue$3,562,000

Net loss of $53.5M vs $43.6M YoY; revenue $3.6M up from $1.6M on license revenue.
Cash $586.6M; runway into H2 2029; R&D down 19% to $29.2M, SG&A up 84% to $20.1M.
FDA Type B meeting scheduled Q2 2026 for AMT-130; UK MAA submission expected Q3 2026.
AMT-260 cohort 2 enrollment on track mid-2026; data from first cohort at June 2026 conference.
AMT-191 dosing paused at mid/high dose due to liver enzyme DLTs; all 11 patients off ERT.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

uniQure N.V. reported financial results for first quarter of 2026.

Period: first quarter of 2026
Result: reported results

Exact text from the filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

uniQure N.V. reported financial results for first quarter of 2026.

Period: first quarter of 2026
Result: reported results

Exact text from the filing

Strong balance sheet with $586.6 million in cash, cash equivalents and current investment securities as of March 31, 2026 and runway into the second half of 2029

View on SEC.gov

Browse all earnings releases →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001104659-26-055242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.